Previous Close | 97.27 |
Open | 96.95 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 800 |
Day's Range | 95.90 - 97.02 |
52 Week Range | 81.96 - 108.78 |
Volume | |
Avg. Volume | 1,387,331 |
Market Cap | 197.832B |
Beta (5Y Monthly) | 0.46 |
PE Ratio (TTM) | 23.40 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.78 (3.94%) |
Ex-Dividend Date | Mar 07, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge erred in dismissing the case, in part for having applied an improper legal standard to Regeneron's claims. Regeneron in a statement said it was "encouraged by the 2nd Circuit’s decision" and looked forward to "further advancing our position in future proceedings."
Key Insights Novartis' significant individual investors ownership suggests that the key decisions are influenced by...